Table III.
Phenotypic method | n (%) | Sensitivity% (CI) |
---|---|---|
MHT | 20 (20.4) | 18 (0.11-0.26) |
IMI-IMI/EDTA E-test | 105 (94.6) | 95.4 (0.89-0.98) |
MERO-MERO/EDTA E-test | 51 (69.8) | 67 (0.58-0.74) |
CAZ + 2 MPA | 102 (90.3) | 92.7 (0.85-0.96) |
CPM + 2 MPA | 96 (85.7) | 87 (0.79-0.92) |
IMI-IMI + 2 MPA | 77 (69.4) | 71 (0.60-0.78) |
MERO-MERO + 2 MPA | 3 (2.99) | 0.27 (0.07-0.8) |
EDTA impregnated IMI disc | 79 (68.7) | 71 (0.62-0.79) |
EDTA impregnated CAZ disc | 77 (65.25) | 70 (0.60-0.78) |
IMI + BA disc | 60 (54.1) | 54 (0.44-0.63) |
MERO + BA disc | 41 (36.6) | 37 (0.28-0.47) |
CTN + BA disc | 23 (21.5) | 20 (0.13-0.29) |
CPM + BA disc | 57 (50.4) | 51 (0.42-0.61) |
CEF + BA disc | 47 (43.5) | 42 (0.33-0.52) |
CAZ + BA disc | 34 (30.1) | 69 (0.59-0.77) |
CTX + BA disc | 46 (44.6) | 41 (0.32-0.51) |
MHT, modified Hodge test; IMI, imipenem; MERO, meropenem; MPA, mercaptonoic acid inhibition test; EDTA, ethylenediaminetetraacetic acid; CAZ, ceftazidime; BA, boronic acid; CTN, cefoxitin; CPM, cefepime; CEF, cefoxitin; CTX, cefotaxime; CI, confidence interval